Basilea Pharmaceutica AG BPMUF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.50% | 16.99% | -6.11% | -7.65% | 35.40% |
| Total Other Revenue | 107.00% | 127.39% | 153.39% | 149.24% | 388.49% |
| Total Revenue | 19.51% | 31.28% | 6.74% | 4.99% | 49.38% |
| Cost of Revenue | 15.97% | 27.40% | 41.79% | 39.47% | 32.53% |
| Gross Profit | 24.84% | 37.14% | -26.24% | -27.44% | 84.82% |
| SG&A Expenses | 7.36% | 17.94% | 23.01% | 21.00% | 24.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.13% | 25.37% | 38.05% | 35.79% | 30.64% |
| Operating Income | 37.06% | 50.56% | -41.30% | -42.26% | 180.89% |
| Income Before Tax | 73.49% | 90.58% | -44.91% | -45.81% | 189.51% |
| Income Tax Expenses | 23.77% | 35.95% | 158.65% | 157.69% | 128.96% |
| Earnings from Continuing Operations | 84.64% | 102.83% | -52.75% | -53.53% | -16.46% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.64% | 102.83% | -52.75% | -53.53% | -16.46% |
| EBIT | 37.06% | 50.56% | -41.30% | -42.26% | 180.89% |
| EBITDA | 32.76% | 45.84% | -39.41% | -40.40% | 172.58% |
| EPS Basic | 82.83% | 100.71% | -53.32% | -54.08% | -17.92% |
| Normalized Basic EPS | 67.64% | 84.06% | -45.57% | -46.46% | 193.34% |
| EPS Diluted | 71.70% | 92.55% | -50.70% | -51.51% | -17.92% |
| Normalized Diluted EPS | 53.73% | 86.50% | -43.41% | -44.34% | 206.04% |
| Average Basic Shares Outstanding | 1.00% | 1.05% | 1.21% | 1.21% | 1.77% |
| Average Diluted Shares Outstanding | 10.13% | -0.28% | -2.64% | -2.64% | -2.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |